Since it is impossible to distinguish the tumor cell or immune cell-derived suPAR in human patients, measurement of the uPAR expression in the primary tumors combined with suPAR levels in the blood may be necessary to better understand the role of uPAR in cancers. This evidence concerns the gene PLAUR and neoplasm.